Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Erythrocyte-Specific Antibodies As a Potential New Therapeutic Modality in Autoimmune and Inflammatory Disorders Beyond Immune Thrombocytopenia (ITP)

Andrew R Crow, BRT, Rick Kapur, MDPhDMSc, Mark Jen, MSc, Patrick J Mott, MSc, Danielle Marjoram, MSc, Alaa Amash, PhD, Simrat S Kahlon, BSc, Issaka Yougbare, PhD, Heyu Ni, MD MSc, PhD, Michael Kim, BSc, John W Semple, PhD, Alan H Lazarus, PhD

Blood (2017) 130 (Supplement 1): 231.

https://doi.org/10.1182/blood.V130.Suppl_1.231.231

Published: 2017

Journal Articles

Amelioration of Immune Thrombocytopenia in Human CD44 Transgenic Mice By Anti-Human CD44 Antibodies

Andrew R. Crow, BSc, Alaa Amash, PhD, Alan H Lazarus, PhD

Blood (2016) 128 (22): 167.

https://doi.org/10.1182/blood.V128.22.167.167

Published: 2016

Journal Articles

CD44 Antibody Mediated Amelioration of Murine ITP: Evidence for a Similar Strain Dependent FcγRIIB Requirement As Compared to Ivig

Andrew R. Crow, BSc, Alan H Lazarus, PhD

Blood (2012) 120 (21): 1084.

https://doi.org/10.1182/blood.V120.21.1084.1084

Published: 2012

Journal Articles

Ivig, but Not a Monoclonal Anti-RBC Antibody, Requires the Presence of Gr-1 + Cells to Ameliorate Immune Thrombocytopenia in a Murine Model

Andrew R. Crow, BSc, Alan H Lazarus, PhD

Blood (2012) 120 (21): 268.

https://doi.org/10.1182/blood.V120.21.268.268

Published: 2012

Journal Articles

The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody–mediated amelioration of murine immune thrombocytopenia

Andrew R. Crow, Sara J. Suppa, Xi Chen, Patrick J. Mott, Alan H. Lazarus

Blood (2011) 118 (24): 6403–6406.

https://doi.org/10.1182/blood-2011-08-374223

Published: 2011

Includes: Supplemental data

Journal Articles

Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?

Andrew R. Crow, Seng Song, Sara J. Suppa, Shuhua Ma, Michael P. Reilly, Pierrette Andre, Steven E. McKenzie, Alan H. Lazarus

Blood (2011) 117 (3): 971–974.

https://doi.org/10.1182/blood-2010-05-280115

Published: 2011

Includes: Supplemental data

Journal Articles

Amelioration of Murine Immune Thrombocytopenia by CD44 Antibodies: a Potential Therapy for ITP?

Andrew R. Crow, Seng Song, Sara J Suppa, Alan H Lazarus, PhD

Blood (2010) 116 (21): 2528.

https://doi.org/10.1182/blood.V116.21.2528.2528

Published: 2010

Journal Articles

Expression of the Neonatal Fc Receptor FcRn Is Not Required for the Amelioration of Murine ITP by IVIg or a Monoclonal Antibody

Andrew R. Crow, Sara J Suppa, Alan H Lazarus, PhD

Blood (2010) 116 (21): 2529.

https://doi.org/10.1182/blood.V116.21.2529.2529

Published: 2010

Journal Articles

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

Anna Podolanczuk, Alan H. Lazarus, Andrew R. Crow, Elliot Grossbard, James B. Bussel

Blood (2009) 113 (14): 3154–3160.

https://doi.org/10.1182/blood-2008-07-166439

Published: 2009

Includes: Supplemental data

Journal Articles

IVIg-Primed Splenocytes Ameliorate Murine ITP in an MHC Class II-Unrestricted Manner.

Andrew R. Crow, BRT, Vinayakumar Siragam, PhD, John Freedman, MD, Alan H. Lazarus, PhD

Blood (2007) 110 (11): 102.

https://doi.org/10.1182/blood.V110.11.102.102

Published: 2007

Journal Articles

IVIg-Primed Leukocytes Offer Longer Protection in the Amelioration of ITP Than IVIg.

Andrew R. Crow, BSc, Davor Brinc, BSc, Vinayakumar Siragam, PhD, John Freedman, MD, Alan H. Lazarus, PhD

Blood (2006) 108 (11): 703.

https://doi.org/10.1182/blood.V108.11.703.703

Published: 2006

Journal Articles

A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

Andrew R. Crow, Seng Song, John W. Semple, John Freedman, Alan H. Lazarus

Blood (2006) 109 (1): 155–158.

https://doi.org/10.1182/blood-2006-05-023796

Published: 2006

Includes: Supplemental data

Journal Articles

Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo

Rukhsana Aslam, Edwin R. Speck, Michael Kim, Andrew R. Crow, K. W. Annie Bang, Frederick P. Nestel, Heyu Ni, Alan H. Lazarus, John Freedman, John W. Semple

Blood (2006) 107 (2): 637–641.

https://doi.org/10.1182/blood-2005-06-2202

Published: 2006

Journal Articles

Inhibition of Immune Thrombocytopenic Purpura (ITP) by an Orally Bioavailable Inhibitor of Syk Kinase Activity.

Andrew R. Crow, BSc, Vinayakumar Siragam, PhD, John Freedman, MD, Elliott B. Grossbard, MD, Esteban S. Masuda, PhD, Polly Pine, PhD, Alan H. Lazarus, PhD

Blood (2005) 106 (11): 2165.

https://doi.org/10.1182/blood.V106.11.2165.2165

Published: 2005

Journal Articles

Monoclonal IgG Specific for the CD44 Antigen Mimics the Action of IVIg in the Amelioration of ITP.

Seng Song, MD, Andrew R. Crow, MSc, Vinayakumar Siragam, PhD, John Freedman, MD, Alan Lazarus, PhD

Blood (2005) 106 (11): 2170.

https://doi.org/10.1182/blood.V106.11.2170.2170

Published: 2005

Journal Articles

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg

Seng Song, Andrew R. Crow, Vinayakumar Siragam, John Freedman, Alan H. Lazarus

Blood (2005) 105 (4): 1546–1548.

https://doi.org/10.1182/blood-2004-05-1886

Published: 2005

Includes: Supplemental data

Journal Articles

A Role for IL-1Receptor Antagonist in the Acute Therapeutic Effects of IVIg?.

Andrew R. Crow, BSc, Seng Song, MD, John Freedman, MD, John W. Semple, PhD, Alan H. Lazarus, PhD

Blood (2004) 104 (11): 2064.

https://doi.org/10.1182/blood.V104.11.2064.2064

Published: 2004

Journal Articles

Can IVIg Preparations with Specificity for Soluble Antigens Mimic the Therapeutic Effects of IVIg in the Treatment of Immune Thrombocytopenia?.

Vinayakumar Siragam, PhD, Davor Brinc, BSc, Andrew R. Crow, BSc, Seng Song, MD, John Freedman, MD, Alan H. Lazarus, PhD.

Blood (2004) 104 (11): 2073.

https://doi.org/10.1182/blood.V104.11.2073.2073

Published: 2004

Journal Articles

IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity

Andrew R. Crow, Seng Song, John Freedman, Cheryl D. Helgason, R. Keith Humphries, Katherine A. Siminovitch, Alan H. Lazarus

Blood (2003) 102 (2): 558–560.

https://doi.org/10.1182/blood-2003-01-0023

Published: 2003

Journal Articles

Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG

Seng Song, Andrew R. Crow, John Freedman, Alan H. Lazarus

Blood (2003) 101 (9): 3708–3713.

https://doi.org/10.1182/blood-2002-10-3078

Published: 2003

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Erythrocyte-Specific Antibodies As a Potential New Therapeutic Modality in Autoimmune and Inflammatory Disorders Beyond Immune Thrombocytopenia (ITP)

Amelioration of Immune Thrombocytopenia in Human CD44 Transgenic Mice By Anti-Human CD44 Antibodies

CD44 Antibody Mediated Amelioration of Murine ITP: Evidence for a Similar Strain Dependent FcγRIIB Requirement As Compared to Ivig

Ivig, but Not a Monoclonal Anti-RBC Antibody, Requires the Presence of Gr-1 + Cells to Ameliorate Immune Thrombocytopenia in a Murine Model

The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody–mediated amelioration of murine immune thrombocytopenia

Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?

Amelioration of Murine Immune Thrombocytopenia by CD44 Antibodies: a Potential Therapy for ITP?

Expression of the Neonatal Fc Receptor FcRn Is Not Required for the Amelioration of Murine ITP by IVIg or a Monoclonal Antibody

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

IVIg-Primed Splenocytes Ameliorate Murine ITP in an MHC Class II-Unrestricted Manner.

IVIg-Primed Leukocytes Offer Longer Protection in the Amelioration of ITP Than IVIg.

A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo

Inhibition of Immune Thrombocytopenic Purpura (ITP) by an Orally Bioavailable Inhibitor of Syk Kinase Activity.

Monoclonal IgG Specific for the CD44 Antigen Mimics the Action of IVIg in the Amelioration of ITP.

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg

A Role for IL-1Receptor Antagonist in the Acute Therapeutic Effects of IVIg?.

Can IVIg Preparations with Specificity for Soluble Antigens Mimic the Therapeutic Effects of IVIg in the Treatment of Immune Thrombocytopenia?.

IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity

Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only